Fremanezumab in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Study Title
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Teva Identifier
TV48125-CNS-30083
ClinicalTrials.gov Identifier
NCT04458857
Study Status
Completed
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab | Drug: Placebo
EudraCT Number
2019-002055-42

Study Description

The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to Fremanezumab. The total duration of the study is planned to be up to 51 months

Print

Click for participation criteria and map of study locations

EudraCT Link


Key Participation Requirements

Gender
Female, Male
Age Range
6 Years to 17 Years
Trial Duration
July 15, 2020 - March 13, 2024
Phase
Phase 3

Study Type

Interventional